▶ 調査レポート

クローン病診断・治療の世界市場:疾患別(回結腸炎、回腸炎 、胃十二指腸のクローン病、空回腸炎、結腸クローン病)、診断別(血液検査、糞便検査、大腸内視鏡検査、軟性S状結腸鏡検査、コンピュータ断層撮影、磁気共鳴断層撮影、カプセル内視鏡、その他)、治療別、地域別分析

• 英文タイトル:Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023)

Mordor Intelligenceが調査・発行した産業分析レポートです。クローン病診断・治療の世界市場:疾患別(回結腸炎、回腸炎 、胃十二指腸のクローン病、空回腸炎、結腸クローン病)、診断別(血液検査、糞便検査、大腸内視鏡検査、軟性S状結腸鏡検査、コンピュータ断層撮影、磁気共鳴断層撮影、カプセル内視鏡、その他)、治療別、地域別分析 / Global Crohn's Disease Diagnostic and Therapeutic Market - Segmented by Type of Disease, Diagnosis, Treatment, and Geography - Growth, Trends, and Forecast (2018 - 2023) / B-MOR-08143資料のイメージです。• レポートコード:B-MOR-08143
• 出版社/出版日:Mordor Intelligence / 2018年5月1日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:Healthcare
• 販売価格(消費税別)
  Single User(1名様用)¥454,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥481,500 (USD4,500)▷ お問い合わせ
  Corporate User¥936,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、クローン病診断・治療の世界市場について調べ、クローン病診断・治療の世界規模、市場動向、市場環境、疾患別(回結腸炎、回腸炎 、胃十二指腸のクローン病、空回腸炎、結腸クローン病)分析、診断別(血液検査、糞便検査、大腸内視鏡検査、軟性S状結腸鏡検査、コンピュータ断層撮影、磁気共鳴断層撮影、カプセル内視鏡、その他)分析、治療別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・クローン病診断・治療の世界市場インサイト
・クローン病診断・治療の世界市場環境
・クローン病診断・治療の世界市場動向
・クローン病診断・治療の世界市場規模
・クローン病診断・治療の世界市場規模:疾患別(回結腸炎、回腸炎 、胃十二指腸のクローン病、空回腸炎、結腸クローン病)
・クローン病診断・治療の世界市場規模:診断別(血液検査、糞便検査、大腸内視鏡検査、軟性S状結腸鏡検査、コンピュータ断層撮影、磁気共鳴断層撮影、カプセル内視鏡、その他)
・クローン病診断・治療の世界市場規模:治療別
・クローン病診断・治療の世界市場:地域別市場規模・分析
・クローン病診断・治療の北米市場規模・予測
・クローン病診断・治療のアメリカ市場規模・予測
・クローン病診断・治療のヨーロッパ市場規模・予測
・クローン病診断・治療のアジア市場規模・予測
・クローン病診断・治療の日本市場規模・予測
・クローン病診断・治療の中国市場規模・予測
・クローン病診断・治療のインド市場規模・予測
・クローン病診断・治療の韓国市場規模・予測
・関連企業情報・競争状況

The global Crohn’s disease diagnostic and therapeutic market is estimated to grow at a good CAGR during the forecast period. Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Affected Population Increasing with Time

It is estimated that around 1.6 million Americans have the inflammatory bowel disease (IBD). This number includes about 780,000 population are having Crohn’s disease, and another 907,000 people are with ulcerative colitis. Research suggests that about six to 15 new cases of Crohn’s disease are diagnosed per 100,000 people each year. People are most frequently diagnosed with Crohn’s disease and ulcerative colitis in the late adolescence or in early adulthood, even though the diagnosis may happen at any age. Many population-based research studies have shown that Crohn’s disease is somewhat more common in women than men, while ulcerative colitis is slightly more common in men than women. As the prevalence of the disease increases, it is expected to drive the Crohn’s disease diagnostic and therapeutic market.
Also, the increasing demand for prompt diagnosis and multiple symptoms associated with the disease requiring individual therapeutic attention, are increasing the growth of the market.

Lack of a Cost-effective Treatment

Current costs for the treatment and diagnosis of Crohn’s disease is high, due to the availability of several new therapeutic drugs and changes in the surgical treatment of the disease. For example, the total cost of Crohn’s disease in the United States is around USD 3.6 billion every year, and the average yearly medical cost per patient is about USD 8,265, with more than one-third of that cost being medications. Biologic medications or drugs are usually expensive. Hospitalization accounted for 31.4% of the cost. On an average, people who have to be hospitalized for Crohn’s disease are expected to spend about 5.8 days in the hospital. All these treatment cost issues are hindering the Crohn’s diagnostic and therapeutic market. Also, as no specific treatment or drug is available in the market, and there is lack of awareness among the people coupled with symptom similarity with other gastrointestinal disease are hindering the market growth.

North America to Lead the Market

North America is dominating the Crohn’s disease diagnostic and therapeutic market due to the increasing prevalence of Crohn’s disease in the region. Asia-Pacific is expected to record a substantial growth in the forecast period.

Key Developments in the Market

• February 2018: AbbVie announced New Phase II data for Upadacitinib showing the clinical and endoscopic outcomes in Crohn’s disease at 52 weeks.

Major Players: ABBVIE, CELGENE CORPORATION, GENENTECH, JANSSEN BIOTECH INC., PFIZER INC., PROMETHEUS LABORATORIES, INC. (NESTLE), SALIX PHARMACEUTICALS, INC. (VALEANT PHARMACEUTICALS), TAKEDA’S PHARMACEUTICAL LTD, and JOHNSON & JOHNSON, among others.

Reasons to Purchase the Report

• Follow the current and future global Crohn’s disease diagnostic and therapeutic market in the developed and emerging markets.
• Analyzing various perspectives of the market with the help of Porter’s
• Five Forces Analysis.
• Identify the segment that is expected to dominate the market.
• Identify the regions that are expected to witness the fastest growth during the forecast period.
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3-month analyst support along with the Market Estimate sheet (in Excel).

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threats of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Drivers
6.1.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
6.1.2 Demand for Prompt Diagnosis
6.1.3 Affected Population Increasing with Time
6.2 Restraints
6.2.1 No Specific Treatment or Drug Available in the Market
6.2.2 Lack of Awareness among the People and Symptom Similarity with Other Gastrointestinal Disease
6.2.3 Lack of a Cost Effective Treatment
6.3 Opportunities
6.3.1 Emergence of Biosimilars
6.4 Key Challenges
7. Market Segmentation
7.1 By Disease
7.1.1 Ileocolitis
7.1.2 Iletis
7.1.3 Gastroduodenal Crohn’S
7.1.4 Jejunoileitis
7.1.5 Crohn’s Colitis
7.2 By Diagnosis
7.2.1 Blood Tests
7.2.2 Fecal Test
7.2.3 Colonoscopy
7.2.4 Flexible Sigmoidoscopy
7.2.5 Computerized Tomography
7.2.6 Magnetic Resonance Imaging
7.2.7 Capsule Endoscopy
7.2.8 Others
7.3 By Treatment
7.3.1 Medication
7.3.1.1 Medication for Inflammation
7.3.1.2 Medication for Immunosuppression
7.3.1.3 Medication for Pain Relief
7.3.2 Surgery
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Abbvie
9.2 Celgene Corporation
9.3 Genetech
9.4 Janssen Biotech Inc.
9.5 Johnson & Johnson
9.6 Pfizer Inc.
9.7 Prometheus Laboratories Inc. (Nestle)
9.8 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
9.9 Takeda’s Pharmaceutical Ltd
*List not Exhaustive
10. Future of the Market
11. Disclaimer